ImmunoGen, Inc. - Product Pipeline Review - H2 2011

Global Markets Direct, September 2011, Pages: 104

ImmunoGen, Inc. – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “ImmunoGen, Inc. – Product Pipeline Review – H2 2011” provides data on the ImmunoGen, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, ImmunoGen, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from ImmunoGen, Inc. and industry–specific third party sources, put together by Global Markets Direct’s team.

Scope

- ImmunoGen, Inc. - Brief ImmunoGen, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of ImmunoGen, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of ImmunoGen, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the ImmunoGen, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate ImmunoGen, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of ImmunoGen, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the ImmunoGen, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with ImmunoGen, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of ImmunoGen, Inc. and identify potential opportunities in those areas.

List of Tables
List of Figures
ImmunoGen, Inc. Snapshot
ImmunoGen, Inc. Overview
Key Information
Key Facts
ImmunoGen, Inc. – Research and Development Overview
Key Therapeutic Areas
ImmunoGen, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
ImmunoGen, Inc. – Pipeline Products Glance
ImmunoGen, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
ImmunoGen, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
ImmunoGen, Inc. – Drug Profiles
IMGN388
Product Description
Mechanism of Action
R&D Progress
IMGN853
Product Description
Mechanism of Action
R&D Progress
IMGN901 + Carboplatin + Etoposide
Product Description
Mechanism of Action
R&D Progress
IMGN901 + Revlimid + Dexamethasone
Product Description
Mechanism of Action
R&D Progress
SAR 566658
Product Description
Mechanism of Action
R&D Progress
ImmunoGen, Inc. – Pipeline Analysis
ImmunoGen, Inc. – Pipeline Products by Therapeutic Class
ImmunoGen, Inc. - Pipeline Products By Target
ImmunoGen, Inc. – Pipeline Products by Route of Administration
ImmunoGen, Inc. – Pipeline Products by Molecule Type
ImmunoGen, Inc. – Recent Pipeline Updates
ImmunoGen, Inc. - Dormant Projects
ImmunoGen, Inc. – Company Statement
ImmunoGen, Inc. – Locations And Subsidiaries
Head Office
ImmunoGen, Inc. - Key Manufacturing Facilities
Recent Developments
Jul 31, 2009: ImmunoGen Announces Encouraging New Clinical Data With IMGN901 Compound In The Treatment Of Small-Cell Lung Cancer
Mar 31, 2005: ImmunoGen, Inc. Files IND For Its HuC242-DM4 Targeted Anticancer Compound
Nov 30, 2010: ImmunoGen Initiates Phase I/II Clinical Trial Of IMGN901 In Small-Cell Lung Cancer
Mar 30, 2011: ImmunoGen Announces Presentations At 102nd Annual Meeting Of American Association For Cancer Research
Mar 30, 2011: ImmunoGen Announces Presentations On IMGN529 At 102nd Annual Meeting Of American Association For Cancer Research
Oct 27, 2008: ImmunoGen, Inc. Earns Milestone Payment From sanofi-aventis With Initiation Of A Phase II Trial With AVE1642
May 26, 2011: ImmunoGen Announces Clinical Presentation Of IMGN901 At ASCO 2011 Annual Meeting
Jun 24, 2005: ImmunoGen, Inc. Announces Initiation Of Clinical Testing Of Its HuC242-DM4 Anticancer Compound; Company's Second Wholly-Owned TAP Compound Advances Into Clinical Testing
Jan 24, 2003: ImmunoGen, Inc. Regains Development and Commercialization Rights for Cantuzumab Mertansine
Sep 21, 2000: HuC242-DM1/SB-408075 Enters Second Phase I/II Clinical Trial
Nov 19, 2010: ImmunoGen Presents Phase I Data Of IMGN388 At EORTC-NCI-AACR Symposium On Molecular Targets And Cancer Therapeutics
May 19, 2005: ImmunoGen, Inc. Announces Presentation Of Preclinical Results Of AVE9633
Aug 18, 2010: ImmunoGen Receives FDA Orphan Drug Designation For Lorvotuzumab Mertansine For Treatment Of Small-Cell Lung Cancer
Nov 17, 2009: ImmunoGen, Inc. Announces Encouraging Clinical Data With Its IMGN901 Compound In The Treatment Of Merkel Cell Carcinoma
Apr 17, 2005: ImmunoGen, Inc. Reports Data At AACR On The Company's HuC242-DM4 Anticancer Compound
Jan 15, 2003: ImmunoGen, Inc Announces Publication Of Cantuzumab Mertansine(huC242-DM1) Phase I Study In The Journal of Clinical Oncology
May 14, 2001: ImmunoGen Reports Promising Results from Phase I/II Human Clinical Study with Product Candidate for Colorectal, Pancreatic and Non-Small-Cell Lung Cancers
Oct 11, 2010: ImmunoGen To Present Encouraging Clinical Data Of Lorvotuzumab Mertansine At ESMO Annual Meeting
Jun 11, 2009: ImmunoGen, Inc. Announces The Discontinuation Of Further Internal Development Of Its IMGN242 Compound
Nov 10, 2001: ImmunoGen Reports Preliminary Phase I/II Clinical Data On huC242-DM1/SB-408075
Dec 09, 2007: ImmunoGena Announces The Clinical Findings With The TAP Compound AVE9633.
Mar 09, 2010: ImmunoGen Wins Orphan Drug Designation For IMGN901 For Treatment Of MCC From FDA And EU COMP
Dec 08, 2008: ImmunoGen, Inc. Announces Favorable IMGN901 Clinical Findings
Dec 08, 2007: ImmunoGen, Inc. Announces Encouraging Clinical Findings For Targeted Anticancer Compounds IMGN901 (HuN901-DM1) And AVE1642
Dec 08, 2007: ImmunoGen, Inc. Announces Encouraging Phase I Clinical Findings Of AVE1642
Nov 08, 2006: ImmunoGen, Inc. Announces Presentation Of HuC242-DM4 Clinical Data At EORTC-NCI-AACR Conference
Aug 08, 2002: ImmunoGen, Inc. And British Biotech Announce Initiation Of Second Phase I Study Of huN901-DM1/BB-10901
May 08, 2001: ImmunoGen Begins Enrollment In A Third Phase I/II Human Clinical Study With Lead Product For Colorectal, Pancreatic And Non-Small-Cell Lung Cancers
Jul 07, 2008: ImmunoGen, Inc. Announces Start of IMGN388 Clinical Testing
Jun 07, 2010: ImmunoGen, Inc. Announces Encouraging IMGN388 Clinical Data Reported At ASCO
Dec 06, 2009: ImmunoGen, Inc. Announces Encouraging Clinical Data With Its IMGN901 Compound In The Treatment Of Multiple Myeloma
Jun 05, 2011: ImmunoGen Announces Positive Clinical Data Presented On IMGN901 In Treatment Of Multiple Myeloma
Dec 04, 2010: ImmunoGen Presents Positive Initial Clinical Data For IMGN901 Used In Combination Regimen For Multiple Myeloma
Oct 04, 2006: ImmunoGen Announces Initiation Of Clinical Testing Of AVE1642 Anticancer Compound In Collaboration With Sanofi-Aventis.
Apr 04, 2011: ImmunoGen Announces First Data For IMGN529 Product Candidate For Non-Hodgkin's Lymphoma
Apr 04, 2011: ImmunoGen Announces First Data For New Therapeutic For Ovarian Cancer And Other Carcinomas
Nov 01, 2001: ImmunoGen Announces Favorable Preliminary Phase I/II Data On huC242-DM1/SB-408075
Aug 01, 2007: ImmunoGen, Inc. Initiates Phase II Clinical Trial Of HuC242-DM4
Jun 01, 2008: ImmunoGen, Inc. Announces Clinical Findings Reported At ASCO With Targeted Anticancer Compounds IMGN242 And AVE1642
Jun 01, 2008: ImmunoGen, Inc. Announces Phase II Clinical Findings With Targeted Anticancer Compounds IMGN242
Jun 01, 2008: ImmunoGen, Inc. Announces The Phase 1 Clinical Findings At ASCO With Targeted Anticancer Compound AVE1642
Feb 01, 2007: BB-10901 Compound Delivers Potent Agent to CD56+ Tumors
Financial Deals Landscape
ImmunoGen, Inc., Deals Volume Summary, 2004 to YTD 2011
ImmunoGen, Inc., Deals Summary By Region, 2004 to YTD 2011
ImmunoGen, Inc., Deals Summary, 2004 to YTD 2011
ImmunoGen, Inc. Detailed Deal Summary
Equity Offering
ImmunoGen Completes Public Offering Of $40 Million
ImmunoGen Completes Private Placement Of $25 Million
Sanofi-Aventis Extends Research Collaboration With ImmunoGen
ImmunoGen Extends Research Agreement With Sanofi-Aventis
ImmunoGen Terminates Co-Development Agreement With Boehringer Ingelheim
Licensing Agreements
ImmunoGen Enters Into Second Licensing Agreement With Amgen
ImmunoGen Enters Into Licensing Agreement With Amgen
ImmunoGen Enters Into Licensing Agreement With Genentech For Cancer Technology
ImmunoGen Enters Into Licensing Agreement With Bayer HealthCare
ImmunoGen Extends Its License Agreement With Sanofi-Aventis
ImmunoGen Enters Into Licensing Agreement With Centocor Ortho Biotech
ImmunoGen Enters Into Licensing Agreement With Sanofi-Aventis
ImmunoGen Enters Into Licensing Agreement With Biotest
ImmunoGen Extends Its Agreement With Millennium Pharmaceuticals
ImmunoGen Enters Into Licensing Agreement With Genentech For Tumor Technology
ImmunoGen Enters Into An Agreement With Genentech
ImmunoGen Enters Into Licensing Agreement With MorphoSys
ImmunoGen Extends Technology Access Agreement With Genentech
ImmunoGen Enters Into Licensing Agreement With Genentech For TAP Technology
ImmunoGen Enters Into License Agreement With Centocor Ortho Biotech
ImmunoGen Enters Into Licensing Agreement With Biogen Idec
ImmunoGen Terminates Licensing Agreement With Vernalis
ImmunoGen Terminates Licensing Agreement With Millennium Pharmaceuticals
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
ImmunoGen, Inc. – Pipeline by Therapy Area and Indication, H2 2011
ImmunoGen, Inc. – Pipeline by Stage of Development, H2 2011
ImmunoGen, Inc. – Monotherapy Products in Pipeline, H2 2011
ImmunoGen, Inc. – Combination Treatment Modalities in Pipeline, H2 2011
ImmunoGen, Inc. - Phase II, H2 2011
ImmunoGen, Inc. - Phase I, H2 2011
ImmunoGen, Inc. - Pipeline By Therapeutic Class, H2 2011
ImmunoGen, Inc. - Pipeline By Target, H2 2011
ImmunoGen, Inc. – Pipeline By Route of Administration, H2 2011
ImmunoGen, Inc. – Pipeline By Molecule Type, H2 2011
ImmunoGen, Inc. – Recent Pipeline Updates, H2 2011
ImmunoGen, Inc. - Dormant Developmental Projects, 2010
ImmunoGen, Inc., Key Manufacturing Facilities
ImmunoGen, Inc., Deals Summary, 2004 to YTD 2011
ImmunoGen, Inc., Deals Summary by Region, 2004 to YTD 2011
ImmunoGen, Inc., Deals Summary, 2004 to YTD 2011

List of Figures
ImmunoGen, Inc. – Pipeline by Therapy Area and Indication, H2 2011
ImmunoGen, Inc. – Pipeline by Stage of Development, H2 2011
ImmunoGen, Inc. – Monotherapy Products in Pipeline, H2 2011
ImmunoGen, Inc. – Combination Treatment Modalities in Pipeline, H2 2011
ImmunoGen, Inc. – Pipeline By Therapeutic Class, H2 2011
ImmunoGen, Inc. - Pipeline By Target, H2 2011
ImmunoGen, Inc. – Pipeline By Route of Administration, H2 2011
ImmunoGen, Inc. – Pipeline By Molecule Type, H2 2011

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Scientific Games Corporation - Company Analysis
• eBay - Strong Execution
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Ixia - Company Analysis
• Amazon - Point of Realization in 2013?
• Analysis of Google Inc
• Cisco - A Tenuous Turnaround
• SunGard - Profile - US